Market Features
7 Expert Stock Picks for September
Stock Pick #7 - Jazz Pharmaceuticals
Recommended by: Hilary Kramer, editor of GameChangers Strategy: Innovative picks that are redefining their sector of the market Neurology and psychiatry have remained two relatively underserved markets in the health sector, and Jazz Pharmaceuticals (JAZZ) is stepping into that void. The first innovative treatment Jazz has on the market is Xyrem, a narcolepsy treatment. In the last quarter, sales of Xyrem were very impressive. Revenues were $28.7 million, up 62% from $17.7 million in the first quarter of 2009. Its other drug is called Luvox and treats obsessive-compulsive disorder. Luvox's sales grew nearly as much as Xyrem's in the first quarter. Revenues were $5.5 million, a 54% increase from $3.6 million the year before. In general, the company's first quarter was their "turnaround" quarter, which means Jazz crossed the threshold into profitability. Net income for the quarter was $1.5 million, or $0.04 per diluted share, compared to a net loss of $13.0 million, or $0.45 per diluted share, for the year-earlier quarter. This tells me this innovative company is really hitting its stride in 2010. A few more breakout drugs, and Jazz could really take off.|
More From Investor Place |
| Top 6 Stocks for August |
| 9 of the Worst Blue Chips Out There |
| Three Good Dividend Stocks to Buy on Bad Days |
TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.26
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet